Bio

Bio


Associate Director, Neuromuscular Medicine Fellowship
Co-Director, Center for Peripheral Nerve Surgery

Clinical Focus


  • Peripheral Nerve Trauma
  • Peripheral Nerve Injury
  • Neurology
  • ALS (Amyotrophic Lateral Sclerosis)
  • CIDP
  • Guillain-Barre Syndrome
  • Lambert-Eaton Myasthenic Syndrome
  • Muscular Dystrophies
  • Myasthenia Gravis
  • Myopathy
  • Rod Myopathy
  • Peripheral Neuropathy

Academic Appointments


Administrative Appointments


  • Clinical Assistant Professor, Neuromuscular Disorders & General Neurology, University Healthcare Alliance, a physician network serving patients around the Bay Area (2014 - Present)
  • Associate Director, Neuromuscular Medicine Fellowship, Stanford University School of Medicine (2015 - Present)
  • Clinical Assistant Professor, Neuromuscular Disorders & General Neurology, Stanford University School of Medicine (2014 - Present)

Honors & Awards


  • American Academy of Neurology Resident Scholarship, American Academy of Neurology (2012)
  • Neurology Medical Student Clerkship Teaching Award, Stanford Department of Neurology (2012)
  • Neurology Medical Student Clerkship Teaching Award, Stanford Department of Neurology (2010)
  • Nomination for Golden Apple Teaching Award, New Jersey Medical School (2009)
  • American Academy of Neurology Medical Student Prize, American Academy of Neurology (2008)
  • Member, Arnold P. Gold Humanism Honor Society (2008)
  • Member, Alpha Omega Alpha Medical Honor Society (2008)
  • Member, Phi Beta Kappa (2004)

Boards, Advisory Committees, Professional Organizations


  • Member, American Association of Neuromuscular and Electrodiagnostic Medicine (2012 - Present)
  • Member, American Academy of Neurology Neuromuscular Section (2012 - Present)
  • Member, American Academy of Neurology (2009 - Present)

Professional Education


  • Board Certification: Electrodiagnostic Medicine, American Board of Electrodiagnostic Medicine (2015)
  • Board Certification: Neurology, American Board of Psychiatry and Neurology (2012)
  • Board Certified, Electrodiagnostic Medicine, American Board of Electrodiagnostic Medicine (2015)
  • Board Certified, Neuromuscular Medicine, American Board of Psychiatry and Neurology (2014)
  • Board Certified, Neurology, American Board of Psychiatry and Neurology (2012)
  • Research Fellowship, Respiratory dysfunction in ALS, California Pacific Medical Center, Forbes Norris MDA/ALS Research Center (2014)
  • Fellowship, Neuromuscular Medicine, Stanford University School of Medicine (2014)
  • Fellowship, EMG/Clinical Neurophysiology, Stanford University School of Medicine (2013)
  • Residency, Neurology, Stanford Hospital & Clinics (2012)
  • Internship, Internal Medicine, New Jersey Medical School (2009)
  • Medical Education, New Jersey Medical School (2008)

Community and International Work


  • Clinical Instructor, Krakow, Poland

    Topic

    Clinical Neurology

    Partnering Organization(s)

    Jagiellonian University Medical College

    Populations Served

    Medical students

    Location

    International

    Ongoing Project

    No

    Opportunities for Student Involvement

    No

  • Teaching Fellow, Stanford

    Topic

    Human Health and Disease INDE 223

    Partnering Organization(s)

    Stanford School of Medicine

    Populations Served

    Medical students

    Location

    Bay Area

    Ongoing Project

    No

    Opportunities for Student Involvement

    No

  • Co-Founder and Director, PINACLE (Partnership in Newark Advocating Community Leaders' Empowerment), Newark, NJ

    Topic

    Community Medical Education

    Partnering Organization(s)

    New Jersey Medical School

    Populations Served

    Patients and community members

    Location

    International

    Ongoing Project

    Yes

    Opportunities for Student Involvement

    No

  • Student Director, Mini-Med School, Newark, NJ

    Topic

    Community Medical Education

    Partnering Organization(s)

    New Jersey Medical School

    Populations Served

    Adults and high school students

    Location

    US

    Ongoing Project

    No

    Opportunities for Student Involvement

    No

Research & Scholarship

Clinical Trials


  • Embodied Virtual Reality Therapy for Functional Neurological Symptom/ Conversion Disorder Recruiting

    The purpose of this study is to design and test the safety and feasibility of virtual reality technologies and experiences of egocentric avatar embodiment in the application of physical and cognitive behavior therapy in functional neurological symptom/conversion disorder. Investigators hypothesize that patients will safely use and accept this modality of treatment and will show evidence of a decrease in symptom frequency.

    View full details

  • Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS) Recruiting

    The study is being conducted to determine if DPS treatment for people with ALS and hypoventilation is associated with improved survival or diaphragm function. The primary objective of the study is to conduct a multi-center, randomized controlled clinical trial comparing standard of care (control) to diaphragm stimulator treatment with the NeuRx® Diaphragm Pacing System™ (DPS) with respect to survival. The secondary objective of the study is to conduct a multi-center, randomized controlled clinical trial to compare standard of care treatment (control) to DPS in ALS subjects with hypoventilation.

    View full details

  • Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy (MTM) Recruiting

    This is a prospective, non-interventional, longitudinal study of the natural history and function of approximately 60 patients with MTM from the United States, Canada and Europe. The duration of the study, including the enrollment period, will be 36 months. Data from the study will be used to characterize the disease course of MTM and determine which outcome measures will be the best to assess the efficacy of potential therapies.

    View full details

  • A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 Not Recruiting

    This study will test the safety, tolerability, and pharmacokinetics of multiple escalating doses of ISIS-DMPKRx administered subcutaneously to adult patients with DM1.

    Stanford is currently not accepting patients for this trial. For more information, please contact Shirley Paulose, 650-725-4341.

    View full details

  • Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) Recruiting

    The purpose of this study is to determine if eculizumab is safe and effective for the treatment of refractory generalized Myasthenia Gravis.

    View full details

  • A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) Not Recruiting

    A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).

    Stanford is currently not accepting patients for this trial.

    View full details

Projects


  • Subject Database and Specimen Repository for Neuromuscular and Neurodegenerative Disorders, Stanford University

    This is a study that involves collecting clinical information of subjects (patients with any neurological condition or their close family member) and tissue samples to develop a subject database and tissue bank, which will be of great value in helping the investigators learn more about various related neurological conditions. This also includes a Biobank.

    Location

    Stanford, CA

    Collaborators

    • JW Day, Professor, Stanford University
  • Clinical and Genetic Characterization of Myotonic Dystrophy, Stanford University

    This is an umbrella protocol for Myotonic Dystrophy to study various aspects of the disease including sleep abnormalities.

    Location

    Stanford, CA

    Collaborators

    • JW Day, Professor, Stanford University

Teaching

Graduate and Fellowship Programs


  • Neurophysiology (Fellowship Program)

Publications

All Publications


  • Phrenic nerve conduction studies as a biomarker of respiratory insufficiency in amyotrophic lateral sclerosis AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION Jenkins, J. A., Sakamuri, S., Katz, J. S., Forshew, D. A., Guion, L., Moore, D., Miller, R. G. 2016; 17 (3-4): 213-220

    Abstract

    Our objective was to examine the value of phrenic nerve conduction studies (PNCS) in quantifying diaphragm dysfunction in ALS, as no ideal test of respiratory insufficiency exists in ALS. We prospectively recorded bilateral PNCS, forced vital capacity (FVC), maximum inspiratory pressure (MIP), sniff nasal inspiratory pressure (SNIP), respiratory rate, ALSFRS-R, and respiratory symptoms in 100 ALS patients attending our clinic over a nine-month period. Survival data were collected for two years. Results showed that PNCS were reproducible and well tolerated. When the Pamp was abnormal (<0.3 mV), the relative risk of a respiratory rate >18 was 7.2 (95% CI 2.2-37.2, p <0.01) compared with a Pamp ≥0.3 mV. Similarly, the relative risk of orthopnea was 3.5 (95% CI 1.6-8.7, p <0.01) and dyspnea 2.4 (95% CI 1.4-4.0, p <0.01). FVC had the strongest correlation with Pamp (R(2) = 0.48 (p <0.001)). Fourteen of 15 patients with a FVC <50% had a Pamp <0.3 mV. However, eight with a Pamp <0.3 had a FVC >80%. The median survival was 1.07 years when the Pamp was <0.3 mV and >2 years when the Pamp was >0.3 mV (p <0.001). In conclusion, the phrenic Pamp correlated closely with multiple symptoms, signs, and laboratory measures of respiratory insufficiency and may prove to be a useful biomarker of respiratory dysfunction in ALS.

    View details for DOI 10.3109/21678421.2015.1112406

    View details for Web of Science ID 000374776900008

    View details for PubMedID 26618854

  • Congenital muscular dystrophy and generalized epilepsy caused by GMPPB mutations. Brain research Raphael, A. R., Couthouis, J., Sakamuri, S., Siskind, C., Vogel, H., Day, J. W., Gitler, A. D. 2014; 1575: 66-71

    Abstract

    The alpha-dystroglycanopathies are genetically heterogeneous muscular dystrophies that result from hypoglycosylation of alpha-dystroglycan (α-DG). Alpha-dystroglycan is an essential link between the extracellular matrix and the muscle fiber sarcolemma, and proper glycosylation is critical for its ability to bind to ligands in the extracellular matrix. We sought to identify the genetic basis of alpha-dystroglycanopathy in a family wherein the affected individuals presented with congenital muscular dystrophy, brain abnormalities and generalized epilepsy. We performed whole exome sequencing and identified compound heterozygous GMPPB mutations in the affected children. GMPPB is an enzyme in the glycosylation pathway, and GMPPB mutations were recently linked to eight cases of alpha-dystroglycanopathy with a range of symptoms. We identified a novel mutation in GMPPB (p.I219T) as well as a previously published mutation (p.R287Q). Thus, our work further confirms a role for GMPPB defects in alpha-dystroglycanopathy, and suggests that glycosylation may play a role in the neuronal membrane channels or networks involved in the physiology of generalized epilepsy syndromes. This article is part of a Special Issue entitled RNA Metabolism 2013.

    View details for DOI 10.1016/j.brainres.2014.04.028

    View details for PubMedID 24780531

  • Perioperative ischemic optic neuropathy (POION). Spine Bennett, H. L., Origlieri, C., Sakamuri, S. 2005; 30 (23): 2706-?

    View details for PubMedID 16319759